A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.

Saved in:
Bibliographic Details
Title: A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
Authors: Sternberg, C.N.1 cns9006@med.cornell.edu, Saad, F.2, Graff, J.N.3, Peer, A.4, Vaishampayan, U.N.5, Leung, E.6, Rosenbaum, E.7, Gurney, H.8, Epstein, R.J.9, Davis, I.D.10,11, Wu, B.12, Trandafir, L.13, Wagner, V.J.13, Hussain, M.14
Source: Annals of Oncology. Feb2020, Vol. 31 Issue 2, p257-265. 9p. 1 Diagram, 3 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2019.10.025